A New Conversation About Cancer Therapy

Cancer draws each patient into an unhealthy molecular dialogue.


What new outcomes could be achieved if a patient’s therapy were designed to change the dialogue between tumor and immune cells?

Cancer therapy should work better for patients.


Current immunotherapies, which have doubled response rates over first-line chemotherapies, still only improve long-term survival in 20%-40% of cancer patients.  

Eloquent™ Immunotherapy changes the conversation for cancer patients

Qrono is actively developing patentable therapies that change cancer-immune cell communication.  Our aim is to create cost-effective, low-toxicity treatment options for activating anti-cancer immune cells or for turning “cold” tumors “hot”, outcomes which are rarely realized for patients on current chemo- or immunotherapies.